HCPCS Level II code M0222 denotes the intravenous injection of bebtelovimab and includes medication administration plus post-administration monitoring. This code captures a single-service encounter for delivery of a monoclonal antibody and the immediate observation period that follows, reflecting how payers identify and reimburse outpatient biologic injections. Nationally, accurate use of M0222 affects clinical documentation, claims processing, and reporting for COVID-19 targeted therapies and other monoclonal antibody treatments.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing benchmarks where available, and relevant policy considerations impacting access and payment for monoclonal antibody injections administered in outpatient infusion settings.

Readers will learn the clinical and billing context for M0222, typical sites of service for administration, common billing modifiers supplied in input, and where to find related billing references. The summary also signals areas where input data was not provided and where readers should seek payer-specific policies or client-specific fee schedules for reimbursement details.